Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF ‐β1/Smad3 signalling pathway

Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial

(2021) Gavin A. Lewis et al.   NATURE MEDICINE

Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK

(2021) Hongyang Shu et al.   Frontiers in Pharmacology

Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease

(2020) Saleela M Ruwanpura et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Heat shock transcription factor 1 regulates exercise‐induced myocardial angiogenesis after pressure overload via HIF‐1α/VEGF pathway

(2020) Xu Tian et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways

(2020) Qun Lv et al.   MOLECULAR MEDICINE

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

(2020) Mark Sweeney et al.   EMBO Molecular Medicine

Treatment and Control of Hypertension in 2020

(2020) Gregory Curfman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin

(2019) Hairuo Lin et al.   CARDIOVASCULAR RESEARCH

Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways

(2019) Yu Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment

(2018) Lin Chen et al.   BIOMEDICINE & PHARMACOTHERAPY

Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology

(2018) Steven J. Forrester et al.   PHYSIOLOGICAL REVIEWS

Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis

(2017) Hadi Khalil et al.   JOURNAL OF CLINICAL INVESTIGATION

Heat shock transcription factor 1 protects against pressure overload-induced cardiac fibrosis via Smad3

(2017) Ning Zhou et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis

(2017) Zhenzhen Li et al.   NEPHROLOGY

Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines’ common metabolite against captopril

(2017) Katarzyna A. Mitręga et al.   PLoS One

Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF-β1/Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure

(2016) Feifei Zhang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

(2013) Yongliang Wang et al.   CARDIOLOGY

The pathogenesis of cardiac fibrosis

(2013) Ping Kong et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

(2011) Takanori Yamazaki et al.   HYPERTENSION RESEARCH

Angiotensin-Converting Enzyme Inhibition Promotes Coronary Angiogenesis in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats

(2011) Hiroki Yazawa et al.   JOURNAL OF CARDIAC FAILURE

Effects of Captopril and Telmisartan on Matrix Metalloproteinase-2 and -9 Expressions and Development of Left Ventricular Fibrosis Induced by Isoprenaline in Rats

(2010) Muneyoshi Okada et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment

(2010) W.A. Rocha et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Cardiac fibroblasts: At the heart of myocardial remodeling

(2009) Karen E. Porter et al.   PHARMACOLOGY & THERAPEUTICS